Bibliography
Found 27 results
Filters: Author is McArthur, Justin C [Clear All Filters]
Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system. AIDS. 2020 ;34(13):1975-1977.
. Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients. J Acquir Immune Defic Syndr. 2019 ;82(1):61-70.
. Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology. 2019 ;92(12):e1344-e1353.
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017 ;215(1):105-113.
Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. J Neurovirol. 2016 ;22(5):607-614.
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 ;22(2):170-8.
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol. 2015 ;21(5):559-67.
Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clin Infect Dis. 2015 ;61(9):1476-84.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics. 2012 ;53(4):380-6.
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology. 2012 ;433(2):498-505.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010 ;67(5):552-8.
HIV-associated neurocognitive disorders: is there a hidden epidemic?. AIDS. 2010 ;24(9):1367-70.
. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009 ;23(17):2317-22.
. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.